ScholarIQanswers from OpenAlex
Saitama Cancer Center
InstitutionResearch output, impact & collaborations
Saitama Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Saitama Cancer Center?
ScholarIQrecord summary
Saitama Cancer Center is a research organisation in Saitama, JP. OpenAlex records 4,553 works and 319,770 citations for it. 633 researchers list it as their most recent affiliation.
How many works does Saitama Cancer Center have?
ScholarIQindexed works
Saitama Cancer Center has 4,553 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Saitama Cancer Center have?
ScholarIQcitation count
Saitama Cancer Center has 319,770 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Saitama Cancer Center?
ScholarIQresearcher count
Saitama Cancer Center has 633 researchers in the ScholarIQ index.
What is the average h-index at Saitama Cancer Center?
ScholarIQavg h-index
Saitama Cancer Center has an average h-index of 46 in OpenAlex.
What is the ROR of Saitama Cancer Center?
ScholarIQror
The ROR for Saitama Cancer Center is on the source record.
What is the OpenAlex record for Saitama Cancer Center?
ScholarIQopenalex
The OpenAlex for Saitama Cancer Center is on the source record.
Who are the most-cited researchers behind Saitama Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Saitama Cancer Center?
ScholarIQmost cited works
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akira Fukutomi, Hiroki Hara, Nobumasa Mizuno, Hiroaki Yanagimoto, Keita Wada, Kazutoshi Tobimatsu, Kei Yane, Shoji Nakamori, Hiroyuki Yamaguchi, Akinori Asagi, Seigo Yukisawa, Yasushi Kojima, Ken Kawabe, Yasuyuki Kawamoto, Rie Sugimoto, Tomohisa Iwai, Kazuyoshi Nakamura, Hiroyoshi Miyakawa, Tatsuya Yamashita, A. Hosokawa, Tatsuya Ioka, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Narikazu Boku, Min‐Hee Ryu, Ken Kato, Hyun Cheol Chung, Keiko Minashi, K.-W. Lee, H. Cho, Won Ki Kang, Yoshito Komatsu, Masahiro Tsuda, Kensei Yamaguchi, Hiroki Hara, Soichi Fumita, Mizutomo Azuma, L.-T. Chen, Yoon‐Koo Kang
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
How much of the research on Saitama Cancer Center is open access?
ScholarIQopen access share
80%OPEN ACCESS